Tech group seeks more access to corporate employees in bid for foothold in $4tn healthcare market
Related Posts
Mirum Pharmaceuticals Expands Rare Liver Disease Portfolio with $820 Million Bluejay Therapeutics Acquisition
Mirum Pharmaceuticals (Nasdaq: MIRM), a leading rare disease biopharma, announced a definitive agreement to acquire Bluejay Therapeutics, a privately held biotech focused on viral and liver...
Biocon’s Strategic Integration of Biocon Biologics: A $5.5 Billion Transformation Reshaping Global Biopharmaceutical Leadership
Biotechnology major Biocon has announced a strategic corporate action to fully integrate Biocon Biologics Limited (BBL) as a wholly owned subsidiary into Biocon Limited, valuing the biologics unit...
AbbVie’s $1.2 Billion Psychedelic Bet Signals Strategic Shift as Retail Investors Weigh Post-Humira Growth
AbbVie's recent acquisition of Gilgamesh Pharmaceuticals' psychedelic depression treatment for up to $1.2 billion represents a pivotal moment in the pharmaceutical giant's post-Humira...
Hims & Hers’ Strategic Expansion into Canada: Leveraging ZAVA Acquisition and Generic Semaglutide for Market Disruption
Hims & Hers Health's planned 2026 Canadian expansion represents a pivotal strategic shift, combining its recent acquisition of European digital health platform ZAVA with the anticipated launch of...